Stephanie Moore
Clinical Nurse Specialist · Tulsa, OKNPI 1578834396
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,077, 4.2 times the $259 reported in 2021.
Across 121 payments — averaging $24.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$374
- AstraZeneca$351
- Boehringer Ingelheim$343
- OPKO Pharmaceuticals, LLC$220
- Fresenius USA Marketing, Inc.$166
- Amgen$158
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,000100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 15 | $374 |
| AstraZeneca(2 entities) | 14 | $351 |
| Boehringer Ingelheim | 8 | $343 |
| OPKO Pharmaceuticals, LLC | 12 | $220 |
| Fresenius USA Marketing, Inc. | 8 | $166 |
| Amgen(2 entities) | 9 | $158 |
| Aurinia Pharma U.S., Inc. | 7 | $154 |
| Xeris Pharmaceuticals, Inc. | 1 | $122 |
| Ardelyx, Inc. | 6 | $122 |
| ANI Pharmaceuticals, Inc. | 5 | $104 |
| Calliditas Therapeutics US Inc. | 4 | $100 |
| Inspire Medical Systems, Inc. | 1 | $96 |
| Daiichi Sankyo Inc. | 4 | $85 |
| Abbott | 1 | $84 |
| Mallinckrodt Hospital Products Inc. | 3 | $82 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Novartis | 2 | $45 |
| Sanofi | 1 | $32 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $30 |
| Scpharmaceuticals Inc. | 1 | $27 |
| EMD Serono, Inc. | 1 | $26 |
| Medline Industries LP | 1 | $26 |
| Hologic Sales And Service, LLC | 1 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Taiho Oncology, Inc. | 1 | $22 |
| Merck | 1 | $19 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| Bristol Myers Squibb | 1 | $17 |
| Clovis Oncology, Inc. | 1 | $16 |
| Karyopharm Therapeutics Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Seagen Inc. | 1 | $13 |
| Pfizer | 1 | $13 |
| Epizyme, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$233
- GVOKE HYPOPEN$122
- ULTOMIRIS$106
How this compares
$3,013 in reported general payments places this provider in the 80th percentile of 56 clinical nurse specialist providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 38 | $191,679 |
| LokelmaSodium Zirconium Cyclosilicate | 31 | $19,622 |
| Lanthanum Carbonate | 16 | $15,525 |
| JardianceEmpagliflozin | 23 | $15,062 |
| FarxigaDapagliflozin Propanediol | 16 | $11,676 |
| Sevelamer Carbonate | 56 | $9,747 |
| VeltassaPatiromer Calcium Sorbitex | 21 | $9,078 |
| Torsemide | 252 | $4,692 |
| Telmisartan | 89 | $2,744 |
| Calcium Acetate | 33 | $1,634 |
| Allopurinol | 104 | $1,082 |
| Carvedilol | 94 | $697 |
| Losartan Potassium | 72 | $662 |
| Doxazosin Mesylate | 60 | $642 |
| Amlodipine Besylate | 119 | $605 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $166 | $191,67938 claims |
| AstraZenecaLokelma, Farxiga | $351 | $31,29847 claims |
| Boehringer IngelheimJardiance | $343 | $15,06223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 56 clinical nurse specialist providers in Oklahoma.
Other clinical nurse specialist in Tulsa
- Deborah CrawfordTulsa$11K
- Jessica GriffithTulsa$5K
- Melissa DimickTulsa$4K
- Lindsey RemmertTulsa$3K
- Lauren StegemannTulsa$3K
- Tammy JoplinTulsa$2K
- Libbe MarquezTulsa$2K
- Lisa LeeTulsa$2K
- Kristy MartinTulsa$2K
- Candace CarrTulsa$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.